You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The company's AlloSure Kidney test received coverage, along with its AlloSure Heart test when used with the firm's AlloMap test.
The company plans to show new data for its Signatera oncology test at three upcoming conferences this year, including in breast cancer and bladder cancer.
Product revenues increased 39 percent year over year to $93.3 million, while license and other revenues were down 56 percent to $4.9 million.
The firm recently described circumstances in which the fraction of host or donor DNA could be altered, and plans new approaches to data interpretation.
Of the 32 companies in the index, 14 firms saw their stock prices increase, while 18 firms' share prices decreased.
The company reported $53.4 million in total revenues for the quarter and said testing services revenues rose 61 percent year over year.
Thermo Fisher's transplant diagnostics products include antibody detection assays, post-transplant monitoring solutions, HLA typing products, and lab instrumentation.
A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors.
The company said it provided approximately 21,800 total AlloSure and AlloMap patient results during the quarter.
CareDx hopes the final LCD for AlloSure Heart will lead to an approval of HeartCare, a combination of AlloSure Heart and AlloMap Heart.